Exact Sciences Narrows Q3 Loss on Strong Revenue Growth

Ticker: EXAS · Form: 10-Q · Filed: 2025-11-03T00:00:00.000Z

Sentiment: bullish

Topics: Cancer Diagnostics, Biotechnology, Q3 Earnings, Revenue Growth, Net Loss Reduction, Healthcare, Medical Devices

Related Tickers: EXAS, LH, DGX, ILMN

TL;DR

**EXAS is narrowing its losses and growing revenue, making it a strong buy for long-term growth in cancer diagnostics.**

AI Summary

EXACT SCIENCES CORP (EXAS) reported a net loss of $19.594 million for the three months ended September 30, 2025, a significant improvement from the $38.236 million net loss in the same period of 2024. Revenue increased to $850.739 million for the quarter, up from $708.655 million year-over-year, representing a 20.0% growth. For the nine months ended September 30, 2025, the net loss was $121.994 million, an improvement from $164.272 million in 2024. Total assets slightly decreased to $5.900 billion as of September 30, 2025, from $5.928 billion at December 31, 2024. Cash and cash equivalents rose to $789.037 million from $600.889 million, while marketable securities decreased to $214.058 million from $437.137 million. Operating expenses increased to $609.474 million for the quarter, up from $533.988 million in 2024, driven by higher sales and marketing ($250.228 million vs. $220.264 million) and general and administrative expenses ($241.413 million vs. $193.539 million). The company's strategic outlook involves continued investment in its pipeline for cancer screening and diagnostic tests, building on the success of Cologuard and Oncotype DX.

Why It Matters

This filing shows Exact Sciences is making progress towards profitability, with a significantly reduced net loss and robust revenue growth, which could signal a positive trend for investors. The increase in cash and cash equivalents, despite a decrease in marketable securities, suggests improved operational cash flow, which is crucial for funding ongoing R&D and market expansion. In a competitive diagnostics market, continued investment in its pipeline, as highlighted by the company, is essential to maintain its edge against rivals and deliver innovative solutions to patients and healthcare providers. This financial performance could bolster investor confidence and potentially lead to a re-evaluation of EXAS's stock.

Risk Assessment

Risk Level: medium — While EXAS shows strong revenue growth and reduced net losses, the company still operates at a net loss of $19.594 million for the quarter and has an accumulated deficit of $4.620 billion as of September 30, 2025. This indicates ongoing reliance on cash reserves and potential future financing, despite a healthy cash balance of $789.037 million.

Analyst Insight

Investors should consider EXAS a 'buy' given the significant reduction in net loss and strong revenue growth of 20.0% year-over-year. Monitor future filings for continued progress towards profitability and the impact of pipeline investments on market share and financial performance.

Financial Highlights

debt To Equity
1.36
revenue
$850.739M
operating Margin
-2.99%
total Assets
$5.900B
total Debt
$3.399B
net Income
$(19.594)M
eps
$0.10
gross Margin
68.65%
cash Position
$789.037M
revenue Growth
+20.0%

Revenue Breakdown

SegmentRevenueGrowth
Total Revenue$850.739M+20.0%

Key Numbers

Key Players & Entities

FAQ

What were Exact Sciences' key financial results for the third quarter of 2025?

Exact Sciences reported revenue of $850.739 million for the three months ended September 30, 2025, an increase from $708.655 million in the prior year. The net loss for the quarter significantly improved to $19.594 million, compared to a net loss of $38.236 million in the same period of 2024.

How did Exact Sciences' cash position change in the first nine months of 2025?

As of September 30, 2025, Exact Sciences' cash and cash equivalents increased to $789.037 million from $600.889 million at December 31, 2024. Net cash provided by operating activities was $339.749 million for the nine months ended September 30, 2025.

What is Exact Sciences' strategic focus for future growth?

Exact Sciences is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis. This strategy builds on the success of its existing Cologuard and Oncotype DX tests, aiming to provide clarity for patients and healthcare professionals.

What were the main drivers of operating expenses for Exact Sciences in Q3 2025?

Total operating expenses for Q3 2025 were $609.474 million, up from $533.988 million in Q3 2024. This increase was primarily driven by higher sales and marketing expenses of $250.228 million and general and administrative expenses of $241.413 million.

Did Exact Sciences experience any significant changes in its balance sheet liabilities?

Yes, total current liabilities decreased to $584.260 million as of September 30, 2025, from $732.187 million at December 31, 2024, largely due to the current portion of convertible notes decreasing from $249.153 million to zero.

What is the current risk level for investing in Exact Sciences based on this 10-Q?

The risk level is medium. While Exact Sciences shows strong revenue growth and a reduced net loss, it still operates at a net loss and has a substantial accumulated deficit of $4.620 billion, indicating ongoing financial challenges despite operational improvements.

How has Exact Sciences' net loss per share changed?

The net loss per share for the three months ended September 30, 2025, was $(0.10), a significant improvement from $(0.21) in the same period of 2024. For the nine months, it improved to $(0.65) from $(0.89).

What accounting pronouncements is Exact Sciences evaluating for future adoption?

Exact Sciences is evaluating ASU No. 2023-06 (Disclosure Improvements), ASU No. 2023-09 (Improvements to Income Tax Disclosures), ASU No. 2024-03 (Disaggregation of Income Statement Expenses), and ASU No. 2025-03 (Determining the Accounting Acquirer in the Acquisition of a Variable Interest Entity).

What was the change in Exact Sciences' total stockholders' equity?

Total stockholders' equity increased to $2.501 billion as of September 30, 2025, from $2.402 billion at December 31, 2024. This increase was influenced by stock-based compensation expense and other comprehensive income.

What is the significance of the reclassification of amortization of acquired intangible assets?

Amortization of acquired intangible assets, previously a separate line item, is now presented within cost of sales, research and development, sales and marketing, and general and administrative expenses. This change allows for the presentation of gross profit on the condensed consolidated statements of operations, providing a clearer view of core profitability.

Risk Factors

Industry Context

Exact Sciences operates in the highly competitive and rapidly evolving cancer screening and diagnostics market. Key trends include the increasing demand for early detection methods, advancements in molecular diagnostics, and the integration of AI and machine learning. The company faces competition from both large, established diagnostic companies and smaller, innovative biotech firms.

Regulatory Implications

The company's operations are subject to significant regulatory oversight, particularly from the FDA for its diagnostic tests. Changes in regulatory pathways, approval processes, or post-market surveillance requirements could impact product development and commercialization timelines. Furthermore, evolving reimbursement policies from payers are critical for market access and revenue generation.

What Investors Should Do

  1. [object Object]
  2. [object Object]
  3. [object Object]
  4. [object Object]

Glossary

Accumulated deficit
The total net losses of a company since its inception that have not been offset by net income. (Indicates the company has historically operated at a loss, with the deficit increasing to $4.620 billion as of September 30, 2025.)
Goodwill
An intangible asset that arises when a company acquires another company for a price greater than the fair value of its identifiable net assets. (Represents a significant portion of the company's assets ($2.368 billion), suggesting past acquisitions.)
Marketable securities
Short-term, highly liquid investments that can be readily converted into cash. (Decreased significantly to $214.058 million from $437.137 million, impacting the company's short-term investment portfolio.)
Convertible notes
Debt securities that can be converted into a predetermined amount of the issuer's equity. (The current portion of convertible notes decreased from $249.153 million to zero, indicating a significant portion was paid off or matured.)
Operating lease right-of-use assets
Assets recognized under accounting standards for leases, representing the right to use an asset for the lease term. (These assets, along with corresponding liabilities, reflect the company's leasing arrangements for property and equipment.)

Year-Over-Year Comparison

Exact Sciences demonstrated robust revenue growth of 20.0% year-over-year for the third quarter of 2025, reaching $850.739 million. This top-line expansion contributed to a significant improvement in net loss, which narrowed by 48.7% to $19.594 million compared to the prior year. While total assets saw a slight decrease, cash and cash equivalents increased substantially to $789.037 million, bolstering liquidity. However, operating expenses, particularly in sales and marketing and general and administrative functions, saw notable increases, contributing to the ongoing net loss despite revenue gains.

Filing Stats: 4,523 words · 18 min read · ~15 pages · Grade level 19.3 · Accepted 2025-11-03 17:10:34

Key Financial Figures

Filing Documents

- Financial Information

Part I - Financial Information Item 1.

Financial Statements

Financial Statements Condensed Consolidated Balance Sheets (unaudited) as of September 30, 2025 and December 31, 2024 3 Condensed Consolidated Statements of Operations (unaudited) for the Three and Nine Months Ended September 30, 2025 and 2024 4 Condensed Consolidated Statements of Comprehensive Loss (unaudited) for the Three and Nine Months Ended September 30, 2025 and 2024 5 Condensed Consolidated Statements of Stockholders' Equity (unaudited) for the Three and Nine Months Ended September 30, 2025 and 2024 6 Condensed Consolidated Statements of Cash Flows (unaudited) for the Nine Months Ended September 30, 2025 and 2024 8 Notes to Condensed Consolidated Financial Statements (unaudited) 10 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 37 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 47 Item 4.

Controls and Procedures

Controls and Procedures 48

- Other Information

Part II - Other Information Item 1.

Legal Proceedings

Legal Proceedings 49 Item 1A.

Risk Factors

Risk Factors 49 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 49 Item 3. Defaults Upon Senior Securities 49 Item 4. Mine Safety Disclosures 49 Item 5. Other Information 50 Item 6. Exhibits 51

Signatures

Signatures 52 2 Table of Contents EXACT SCIENCES CORPORATION Condensed Consolidated Balance Sheets (Amounts in thousands, except share data - unaudited)

— Financial Information

Part I — Financial Information September 30, 2025 December 31, 2024 ASSETS Current assets: Cash and cash equivalents $ 789,037 $ 600,889 Marketable securities 214,058 437,137 Accounts receivable, net 306,051 248,968 Inventory 164,784 162,383 Prepaid expenses and other current assets 116,796 122,046 Total current assets 1,590,726 1,571,423 Long-term Assets: Property, plant and equipment, net 704,065 693,673 Operating lease right-of-use assets 121,114 116,952 Goodwill 2,368,028 2,366,676 Intangible assets, net 941,200 1,009,693 Other long-term assets, net 174,876 169,722 Total assets $ 5,900,009 $ 5,928,139 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 129,356 $ 89,572 Accrued liabilities 408,774 328,292 Operating lease liabilities, current portion 31,851 27,405 Convertible notes, net, current portion — 249,153 Other current liabilities 14,279 37,765 Total current liabilities 584,260 732,187 Long-term liabilities: Convertible notes, net, less current portion 2,325,637 2,321,067 Other long-term liabilities 324,807 315,503 Operating lease liabilities, less current portion 163,886 157,133 Total liabilities 3,398,590 3,525,890 Commitments and contingencies (Note 13) Stockholders' equity: Preferred stock, $ 0.01 par value Authorized— 5,000,000 ; shares issued and outstanding— no shares at September 30, 2025 and December 31, 2024 — — Common stock, $ 0.01 par value Authorized— 400,000,000 ; shares issued and outstanding— 189,452,459 and 185,616,438 shares at September 30, 2025 and December 31, 2024 1,896 1,857 Additional paid-in capital 7,116,306 6,899,368 Accumulated other comprehensive income (loss) 3,243 ( 944 ) Accumulated deficit ( 4,620,026 ) ( 4,498,032 ) Total stockholders' equity 2,501,419 2,402,249 Total liabilities and stockholders' equity $ 5,900,009 $ 5,928,139 The accompanying notes are an integral part of these condensed consolidated financial statements. 3 Table of Contents EXAC

Business

Business Exact Sciences Corporation (together with its subsidiaries, "Exact," or the "Company") was incorporated in February 1995. A leading provider of cancer screening and diagnostic tests, Exact Sciences gives patients and health care professionals the clarity needed to take life-changing action earlier. Building on the success of Cologuard and Oncotype DX tests, Exact Sciences is investing in its pipeline to develop innovative solutions for use before, during, and after a cancer diagnosis . Basis of Presentation and Principles of Consolidation The accompanying condensed consolidated financial statements, which include the accounts of the Company and those of its wholly owned subsidiaries and variable interest entities, are unaudited and have been prepared on a basis substantially consistent with the Company's audited financial statements and notes as of and for the year ended December 31, 2024 included in the Company's Annual Report on Form 10-K (the "2024 Form 10-K"). All intercompany transactions and balances have been eliminated upon consolidation. These condensed consolidated financial statements are prepared in conformity with accounting principles generally accepted ("GAAP") in the United States of America ("U.S.") and follow the requirements of the Securities and Exchange Commission ("SEC") for interim reporting. In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting only of adjustments of a normal and recurring nature) considered necessary for a fair statement of its financial position, operating results and cash flows for the periods presented. The condensed consolidated balance sheet at December 31, 2024 has been derived from audited financial statements, but does not contain all of the footnote disclosures from the 2024 Form 10-K. The results of the Company's operations for any interim period are not necessarily indicative of the results of the Company's operations fo

View on Read The Filing